Phase 2 leads the pipeline, while late-stage assets, personalized therapies, and novel inhaled and immune-based approaches offer strategic investment and partnership opportunitiesDublin, Sept. 30, ...
LUND, SE / ACCESS Newswire / September 7, 2026 / AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results